AzurRx BioPharma CEO James Sapirstein to Present at 2021 BIO Digital

Rhea-AI Summary

AzurRx BioPharma, a clinical stage biopharmaceutical company focused on gastrointestinal diseases, announced the participation of CEO James Sapirstein at the 2021 BIO Digital conference on June 10-11 and June 14-18. He will present an overview of the company’s business and pipeline, including anticipated milestones for 2021 and early 2022. The presentation will be available on demand starting June 10, 2021. Additionally, management will engage in one-on-one meetings with registered investors and pharmaceutical executives.

BOCA RATON, Fla., June 08, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that James Sapirstein, Chief Executive Officer of AzurRx, will present at the 2021 BIO Digital. The virtual conference is taking place June 10-11 and June 14-18, 2021.

Details of the event are as follows:

Event:		2021 BIO Digital
Date:		June 10-11 and June 14-18, 2021
Registration:		https://www.bio.org/events/bio-digital/registration

In a prerecorded presentation, Mr. Sapirstein will provide an overview of AzurRx’s business and clinical development programs and discuss anticipated 2021 and early 2022 milestones. The presentation will be available on demand to registered conference attendees beginning at 9 a.m. ET on June 10, 2021.

Additionally, Mr. Sapirstein and members of the AzurRx management team will be participating in virtual one-on-one meetings with registered investors and pharmaceutical company executives.

About AzurRx BioPharma, Inc.
AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company has a pipeline of three gut-restricted GI assets. The lead therapeutic candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis, currently in two Phase 2 clinical trials. AzurRx is launching two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor; FW-1022, for COVID-19 gastrointestinal infections and FW-420, for grade 1 Immune Checkpoint Inhibitor-Associated Colitis and diarrhea in oncology patients. The Company is headquartered in Boca Raton, Florida with clinical operations in Hayward, California. For more information visit www.azurrx.com.

Forward-Looking Statement
This press release may contain certain statements relating to future results which are forward-looking statements. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, depending on factors including whether results obtained in preclinical and nonclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether preliminary or interim results from a clinical trial will be indicative of the final results of the trial; the size of the potential markets for the Company’s drug candidates and its ability to service those markets; and the Company’s current and future capital requirements and its ability to raise additional funds to satisfy its capital needs. Additional information concerning the Company and its business, including a discussion of factors that could materially affect the Company’s financial results are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 under the heading “Risk Factors,” as well as the Company’s subsequent filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

For more information:

AzurRx BioPharma, Inc.
777 Yamato Road
Suite 502
Boca Raton, Florida 33431
Phone: (561) 589-7020
info@azurrx.com

Media contact:

Tiberend Strategic Advisors, Inc.
Johanna Bennett/Ingrid Mezo
(212) 375-2665/(646) 604-5150
jbennett@tiberend.com/imezo@tiberend.com

FAQ

When will AzurRx BioPharma present at the BIO Digital conference?

AzurRx BioPharma will present at the BIO Digital conference on June 10-11 and June 14-18, 2021.

What is the focus of AzurRx BioPharma's clinical programs?

Azurrx BioPharma focuses on developing non-systemic therapies for gastrointestinal diseases, with a pipeline including MS1819 for exocrine pancreatic insufficiency.

What type of events will CEO James Sapirstein participate in during the BIO Digital conference?

James Sapirstein will provide a presentation and participate in virtual one-on-one meetings with registered investors and pharmaceutical executives.

How can I access AzurRx BioPharma's presentation at the conference?

The presentation will be available on demand to registered attendees starting at 9 a.m. ET on June 10, 2021.

What are AzurRx BioPharma's expected milestones for 2021?

The company plans to discuss anticipated milestones for 2021 and early 2022 during the BIO Digital conference presentation.